Journal
TRENDS IN IMMUNOLOGY
Volume 40, Issue 6, Pages 511-523Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.it.2019.04.002
Keywords
-
Categories
Funding
- US National Institutes of Health Mentored Clinical Scientist Development Award [1K08DK114563-01]
- American Gastroenterological Association Research Scholars Award
- National Institutes of Health [R01 AI040614, P01 AI056299, AI108545, HL121363, HL13186]
Ask authors/readers for more resources
Oncology has recently undergone a revolutionary change with widespread adoption of immunotherapy for many cancers. Immunotherapy using monoclonal antibodies against checkpoint molecules, including programmed death (PD)-1, PD ligand (PD-L)1, and cytotoxic T lymphocyte-associated antigen (CTLA)-4, is effective in a significant subset of patients. However, immune-related adverse events (irAEs) have emerged as frequent complications of checkpoint blockade, likely due to the physiological role of checkpoint pathways in regulating adaptive immunity and preventing autoimmunity. As immunotherapy becomes more common, a better understanding of the etiology of irAEs and ways to limit these events is needed. At the same time, studying these new therapy-related disorders provides an opportunity to better understand naturally occurring human autoimmune and Inflammatory disorders, with the potential to improve therapies for canoe. and autoimmune diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available